Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort studyResearch in context

• Ngā kaituhi matua: Hilde S. Ørbo (Author), Taissa de Matos Kasahara (Author), Asia-Sophia Wolf (Author), Kristin H. Bjørlykke (Author), Joseph Sexton (Author), Ingrid Jyssum (Author), Anne T. Tveter (Author), Guri Solum (Author), Ingrid Fadum Kjønstad (Author), Sabin Bhandari (Author), Ingrid E. Christensen (Author), Tore K. Kvien (Author), Andreas Lind (Author), Hassen Kared (Author), Jørgen Jahnsen (Author), Espen A. Haavardsholm (Author), Ludvig A. Munthe (Author), Sella A. Provan (Author), John T. Vaage (Author), Siri Mjaaland (Author), Silje Watterdal Syversen (Author), Kristin K. Jørgensen (Author), Gunnveig Grødeland (Author), Guro Løvik Goll (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2025-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Summary: Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was to assess humoral and cellular immunogenicity of a fifth bivalent vaccine d...